Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abbott Laboratories (ABT) vs ASE Technology Holding Co Ltd (ASX) Price & Performance

Abbott LaboratoriesTrade
ASE Technology Holding Co LtdTrade

Price performance (Past 24H)

Key statistics

Abbott Laboratories vs ASE Technology Holding Co Ltd — how do they compare? Abbott Laboratories trades at $110.91 (market cap $187.95B), while ASE Technology Holding Co Ltd trades at $39.16 (market cap $85.75B). The key difference: Abbott Laboratories is far larger — about 2.2× ASE Technology Holding Co Ltd's market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.

ABTASX
Market Cap
$187.95B$85.75B
Sector
HealthTechnology
52-Week High
$136.62$45.12
52-Week Low
$82.57$9.63
Enterprise Value
$214.96B$90.15B
Dividend Yield
2.32%1.08%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abbott Laboratories

Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.

Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.

ASE Technology Holding Co Ltd

ASE Technology Holding (ASX) trades at $39.56, up 5.23% today, showing strong momentum with three consecutive earnings beats. The stock maintains bullish technical signals with support at $38 and resistance at $40. Recent Q2 2026 results demonstrated robust growth in AI-driven semiconductor packaging demand, with the company increasing 2026 capital expenditure to $10.5 billion to expand capacity.

Outlook remains positive with 80% analyst buy ratings and projected revenue growth to $711.2 billion in 2026. Key risks include high valuation multiples (P/E 47.78) and significant capital investment requirements. The AI semiconductor boom provides substantial growth opportunity, though execution on expansion plans will be critical for sustained performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abbott Laboratories

Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Read more on ABT

About ASE Technology Holding Co Ltd

ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.

Read more on ASX